FLONASE® SENSIMIST™

ALLERGY RELIEF—OFFERS POWERFUL SYMPTOM RELIEF

 

FLONASE® SENSIMIST™ Allergy Relief—offers powerful symptom relief

Same
prescription-strength
as Veramyst®
available OTC
in 60- and 120-metered
spray bottles.

New FLONASE® SENSIMIST™ delivers full prescription-strength fluticasone furoate, available OTC1

For patients with mild to moderate allergies who:

  • Are not well controlled on nonsedating antihistamines
  • Are reluctant to use intranasal sprays

Featuring:

  • 24-hour symptom relief for patients 2 years of age or older1
  • Nighttime relief superior to fexofenadine2

Scent-free spray1

  • No smell
  • Many users report little to no aftertaste3,4

Low volume

  • Spray delivered in a fine, gentle mist that helps minimize potential for postnasal drip5
  • Low volume per dose (110 mcg)*

Innovative side-actuated release button

  • Smaller nozzle for patient comfort
  • Viewing window for patients to see remaining contents
  • Audible click to notify patients when device has administered metered dose

FLONASE® SENSIMIST™ Drug Facts1

Active ingredient: Fluticasone furoate

Uses: Temporarily relieves nasal congestion, runny nose, sneezing, itchy nose, and itchy, watery eyes

Ocular symptom relief indicated for patients aged 12 and older.

VIEW FULL DRUG FACTS

FLONASE® SENSIMIST™ Clinical Profile

Learn more about the NEW FLONASE® SENSIMIST™ clinical profile, including efficacy, patient preference, safety, and more.

VIEW THE CLINICAL PROFILE

RESOURCES

Patient education materials and more

PATIENT TYPES

Explore different patient types and find out which product is right for your patients

DOSING

Learn more about FLONASE® SENSIMIST™ Administration and Dosing

References

1. FLONASE® SENSIMIST™ Drug Facts Label. 2. Andrews CP, et al. Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc. 2009;30(2):128-138. 3. GlaxoSmithKline. A randomized, double-blind, placebo-controlled, parallel-group, multicenter, study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 100mcg for 4 weeks in adult and adolescent subjects (≥12 years of age) with perennial allergic rhinitis (PAR). https://www.gsk-clinicalstudyregister.com/files2/20736.pdf4. Data on file, GlaxoSmithKline. A randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 100mcg for 14 days in adult and adolescent subjects with seasonal allergic rhinitis. https://www.gsk-clinicalstudyregister.com/files2/20737.pdf. 5. Mohar D, LaForce C, Berger W, Lim J, Garris C, Prillaman B, Philpot E:  Efficacy of fluticasone furoate nasal spray in conjunction with patient preference.  Annals of Allergy, Asthma and Immunology, Poster abstract P334. 2009;102(Suppl 1):A114.